Centurion BioPharma Corporation Navigation
  • Home
  • About Centurion
  • Our Technology
    • LADR
    • ACDx
  • Pipeline
  • Publications
  • Contact Us
  • News
  • Home
  • About Centurion
  • Our Technology
    • LADR
    • ACDx
  • Pipeline
  • Publications
  • Contact Us
  • News

News

  • March 12, 2019: Centurion BioPharma Corporation’s Albumin Companion Diagnostic (ACDx) Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

  • February 13, 2019: Centurion BioPharma Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor

  • February 11, 2019: Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy

  • June 4, 2018: Centurion BioPharma Corporation Launches to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates

  • Home
  • About Centurion
  • Our Technology
  • Pipeline
  • Publications
  • Contact Us
  • News

© 2020 Centurion BioPharma Corporation